Incidence of human papillomavirus infections in women aged 27 years and older in the US: A federated data network study.

Ellen Stein¹, Kunal Saxena², Thomas Peer¹, Joseph E Tota³, Xuedan You⁴, Dong Wang³, Ya-Ting Chen², K Arnold Chan¹, Linda M Niccolai⁵

¹TriNetX, LLC, Research, Cambridge, USA.

²Outcomes Research, Value & Implementation, Merck & Co., Inc., Rahway, USA.

³Epidemiology, Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, USA.

⁴Outcomes Research, Value & Implementation, Merck & Co., Inc., Rahway, USA. Electronic address: xue.dan.you@merck.com.

⁵Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, USA.

PubMed DOI

Abstract

OBJECTIVES: The US Advisory Committee on Immunization Practices recommends shared clinical decision-making regarding human papillomavirus (HPV) vaccination for individuals aged 27-45 years. The incidence of HPV infection in this age group is not well-understood. This study assessed anogenital HPV infection incidence in a large cohort of unvaccinated US women aged ≥27 years. METHODS: This retrospe…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.